HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.


PDL BioPharma

Xvivo specializes in medical animation for physicians, drug pharmaceutical companies, biomedical research companies and more.

CEO, Threshold Pharmaceuticals